Cephalon to pay $425M for improper drug marketing

Monday

Drug maker Cephalon has completed a previously announced $425 million civil settlement with federal authorities over off-label drug marketing.

Federal authorities in Philadelphia say Cephalon Inc. marketed three drugs for uses other than what they were federally approved for. Cephalon disclosed the tentative settlement last November.

Authorities say Cephalon marketed one of the drugs, Actiq, for maladies including migraines and injuries. But authorities say the fentanyl lollipop is a highly addictive narcotic approved only for certain cancer patients.

Connecticut Attorney General says Connecticut is receiving just more than $6 million as part of the settlement.

Never miss a story

Choose the plan that's right for you.
Digital access or digital and print delivery.